NovogeneAIT Genomics

NovogeneAIT Genomics is a joint venture between Novogene and AIT Biotech focusing in Asia Pacific, Middle East, and Africa (AMEA) region. Novogene (Stock Ticker : 688315) was founded in Beijing, China, in 2011, with a mission to advance genomics and improve life. We are one of the largest NGS service providers for the research and clinical fields, with presence in Singapore, Japan, Australia, India, Hong Kong, the US, UK, and the Netherlands. We have global sequencing labs in Singapore, China, the US (at The University of California at Davis campus), and the UK (Cambridge). At Novogene, helping our customers to meet their research goals is what truly matters. That is why we place utmost importance on providing reliable and trusted services to our customers. Our end-to-end services manage every aspect of your genomics experiments so you can focus on what you do best and we will take care of everything else. Novogene has strong scientific expertise and experience with 37 NGS-related patents and over 670 research papers with total impact factors at more than 4930, including publications in first-tier journals such as Cell, Nature and Science. To learn more about us, visit en.novogene.com.